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Elevated c-Src protein expression has been shown in breast cancer and in vitro evidence suggests a role in endocrine resistance.
To investigate whether c-Src is involved in endocrine resistance, we examined the expression of both total and activated c-Src in
human breast cancer specimens from a cohort of oestrogen receptor (ER)-positive tamoxifen-treated breast cancer patients. Tissue
microarray technology was employed to analyse 262 tumour specimens taken before tamoxifen treatment. Immunohistochemistry
using total c-Src and activated c-Src antibodies was performed. Kaplan–Meier survival curves were constructed and log-rank test
were performed. High level of nuclear activated Src was significantly associated with improved overall survival (P¼0.047) and lower
recurrence rates on tamoxifen (P¼0.02). Improved patient outcome was only seen with activated Src in the nucleus. Nuclear
activated Src expression was significantly associated with node-negative disease and a lower NPI (Po0.05). On subgroup analysis,
only ER-positive/progesterone receptor (PgR)-positive tumours were associated with improved survival (P¼0.004). This shows that
c-Src activity is increased in breast cancer and that activated Src within the nucleus of ER-positive tumours predicts an improved
outcome. In ER/PgR-positive disease, activated Src kinase does not appear to be involved in de novo endocrine resistance. Further
study is required in ER-negative breast cancer as this may represent a cohort in which it is associated with poor outcome.
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Adjuvant hormone therapy results in substantial improvements in
disease free and overall survival for woman with early hormone
receptor-positive breast cancer (Early Breast Cancer Trialists’
Collaborative Group, 1998, 2005). Despite these benefits, a
substantial proportion of patients will develop de novo or acquired
resistance to hormone therapy and this presents a significant
clinical problem.
The precise molecular mechanisms involved in breast cancer cell
resistance to endocrine therapy is poorly understood but there is
strong evidence suggesting it involves cross talk between the
oestrogen receptor (ER), growth factor receptors and other
downstream cellular signalling pathways (Osborne and Schiff,
2004) resulting in ligand-independent activation of the ER and
tumour cell growth. Indeed, we had earlier shown that HER 1–3
expression is significantly associated with early relapse in an ERþ,
tamoxifen-treated cohort (Tovey et al, 2005). Evidence is now
emerging that endocrine resistance not only results in oestrogen-
independent growth but is also associated with altered cell–cell
and cell–matrix adhesive interactions, promoting a more invasive
phenotype (Hiscox et al, 2006).
c-Src non-receptor tyrosine kinase is overexpressed and
activated in a large number of human malignancies and the
relationship between activation and cancer progression appears
significant (Irby and Yeatman, 2000). The precise mechanism
of its action has not been fully elucidated, but c-Src is known
to interact with a diverse array of molecules, including growth
factor receptors and cell–cell adhesion receptors, integrins and
steroid receptors including the ER (Ishizawar and Parsons,
2004; Shupnik, 2004) promoting tumour cell proliferation,
survival, differentiation, migration and invasion (Frame, 2004;
Yeatman, 2004). Recent in vitro studies have shown the over-
expression and over activity of Src during the acquisition
of tamoxifen resistance in ER-positive cell lines (Hiscox et al,
2005; Planas-Silva et al, 2006). Src inhibition was seen to
significantly reduce the invasive behaviour of these cells. In
addition, inhibition of c-Src has been shown to reduce the
incidence of breast cancer metastases and increase survival in
mice. Progress in knowledge of c-Src in tumour genesis has
resulted in Src kinase inhibition being investigated as a therapeutic
target for anti-invasive therapies in breast cancer (Rucci et al,
2006; Finn et al, 2007).
This study, using a large cohort of ER-positive (þ) tamoxifen-
treated patients, was undertaken to examine if c-Src expression is
involved in de novo resistance to tamoxifen treatment. We
examine the role of c-Src expression in human ER-positive breast
cancers, to determine if in vivo c-Src expression, activation or
cellular location is associated with response to tamoxifen therapy
and patient survival.
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sMATERIAL AND METHODS
Patients and tissues
The local ethics committee granted ethical approval for this study to
utilise a database that details the outcome of ER-positive patients
diagnosed with primary operable breast cancer between 1980 and
1999 treated with adjuvant tamoxifen. Within this cohort all patients
received adjuvant tamoxifen (mean time 4.8 years), 26% of patients
received adjuvant chemotherapy and 18% received adjuvant radio-
therapy. Formalin-fixed paraffin-embedded tissue, taken at the time
of surgical resection, was used for tissue microarray (TMA)
construction, as described earlier (Tovey et al, 2005).
Immunohistochemistry
Immunohistochemistry was performed on 10 normal breast
sections and 10 prostate cancer samples, in addition to the 262
ER-positive breast cancer specimens. Full activation of c-Src
requires phosphorylation at tyrosine (Tyr) 419 in addition to the
absence of phosphorylation at tyrosine 519. A phospho-specific
antibody (Cell Signalling Technology, Inc., Danvers, MA, USA)
raised in rabbit to phosphorylated Y416, SrcpY
416, which
corresponds to human Tyr 419, was used, as described in the
literature (Planas-Silva et al, 2006). In addition, an antibody
recognising Total Src (36D10, Cell Signalling Technology) was
used. Before performing immunohistochemistry, antibody speci-
ficity was confirmed by western blotting (Figure 1). As expected,
activated c-Src, SrcpY
416, was detected as a single 60kDa band and
decreased in response to the Src kinase inhibitor dasatinib.
Titration of the optimal antibody dilution was undertaken in
breast tumour specimens before the procedure.
Tissue sections were dewaxed and rehydrated through graded
alcohols and then subject to heat-induced antigen retrieval by
pressure steaming in preheated 10mM citrate buffer for 5min.
Immunostaining was then performed; sections were first treated
with hydrogen peroxide and then blocked using horse serum,
followed by incubation in primary antibody (1:50 dilution,
SrcpY
416 overnight) (1:200 for Src36D10, 1h). DakoCytomation
EnVision was applied for 30min and sections incubated with DAB
(1:50 dilution). Finally, sections were counterstained, dehydrated
and mounted. Positive and negative (isotype-matched antibody)
control slides were incorporated in each run.
Tissue-staining intensity was scored blind by two independent
observers using a weighted histoscore method (Kirkegaard et al,
2006) also known as the Hscore system (McCarty et al, 1986).
Histoscores were calculated from the sum of (1 % cells staining
weakly positive)þ(2 % cell staining moderately positive)þ
(3 % cells staining strongly positive) with a maximum of 300.
Each cellular location was separately assessed with a weighted
histoscore assigned to any membrane, cytoplasm and nucleus
staining. The histoscores for each core were then averaged. Where
one core was missing the remaining core(s) scores were used. To
determine high and low expression the median value for all scores
was used. The inter-class correlation coefficient (ICCC) for each
protein was calculated to confirm consistency between observers.
Western blot analysis
MCF-7 cells treated with varying concentrations of dasatinib were
lysed in RIPA buffer (50mM Tris pH7.6, 150mM sodium chloride,
1% Triton X-100, 0.5% deoxycholate, 0.1% SDS, 10mM sodium
fluoride, 1mM sodium orthovanadate and 1:100 Calbiochem
protease inhibitor cocktail set 1) and centrifuged at 12000rpm
for 10min, the supernatant was removed and protein concentration
determined using BCA/CuSO4 assay. A total of 40mg of protein per
well was resolved by 4–12% gradient Bis-Tris gel electrophoresis
(Invitrogen, Paisley, UK); proteins were transferred to nitrocellu-
lose membranes (Millipore, Watford, UK), which were blocked for
1h in 5% BSA and probed with primary antibodies: anti-phospho
SrcY
419 (1:10000) and anti-total Src (1:10000 Cell Signalling
Technologies, UK) at 41C overnight. Membranes were then
incubated with secondary antibodies (anti-rabbit 1:5000 or anti-
mouse 1:5000, Cell Signalling Technologies) and visualised with
ECL kit (Amersham, Bucks, UK). Where necessary, the membranes
were stripped by incubating with Re-Blot Plus stripping buffer
(Chemicon, Hampshire, UK) before re-probing with other
antibodies including anti-b-tubulin (HRA) (1:8000, Abcam,
Cambridge, UK) to confirm equal protein loading.
Statistical analysis
The statistical software package SPSS version 11.5 was used for all
analysis. Interclass correlation coefficient was employed to
confirm consistency between observers. Protein expression data
were not normally distributed and are shown as median and inter
quartile ranges. Pearson’s w
2 test was employed to assess
association between staining intensity and known clinical para-
meters, and survival analyses were conducted using Kaplan–Meier
method, curves were compared with the log-rank test. Hazard
ratios (HR) were calculated using Cox regression analysis.
RESULTS
Clinical and pathological characteristics
Clinical and pathological characteristics for all patients (n¼262),
including age, grade, nodal status, histology, size and Nottingham
Prognostic Index are detailed in Table 1. The mean duration of
tamoxifen therapy was 4.82 years. Altogether, 55 patients (21%) had
breast cancer-specific deaths, 77 patients (29.4%) had breast cancer
relapse and 60 of these patients were receiving tamoxifen therapy.
Localisation of Total Src and activated c-Src in normal
breast
Ten normal breast sections were stained for total Src and activated
c-Src. Low expression of total Src was observed in the cytoplasm of
60% and nucleus of 40%, however no activated c-Src expression
was observed at any location.
Localisation of activated c-Src expression in ER-positive
breast cancer tissue
A total of 262 ER-positive tumour samples were analysed for
activated c-Src expression. 57.3% (150 out of 262) of tumours
C1  n M 10 nM 25 nM 75 nM 100 nM
SrcpY416
Total Src
Tubulin
Figure 1 Western blot experiment. Phospho-specific antibody recognis-
ing activated c-Src (SrcpY
416) is shown as a single 60kDa band (lane 1:
control, C). In addition, phosphorylation of c-Src was observed to decrease
after treatment with increasing concentrations of the Src kinase inhibitor
dasatinib (lanes2–6) and total Src was not affected by this. Tubulin was
used as a control.
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sexpressed activated Src in the cytoplasm; median histoscore 20
(interquartile range 0–61.5). 58.4% (153 out of 262) of tumours
expressed activated c-Src in the nucleus; median histoscore 10
(interquartile range 0–45). High levels (greater than the median
value) of activated c-Src expression in the cytoplasm or nucleus
was therefore detectable in over 50% (n¼153) of all ER-positive
breast tumours analysed. 2.7% (7 out of 260, two samples missing)
of tumours expressed activated Src in the membrane, median
histoscore 0. Because of the low rate of membrane expression
observed, it was not deemed appropriate to apply these results to
further statistical tests. To confirm that the antibody was able to
detect membrane staining 10 prostate tumours were also stained
for activated c-Src. Activated c-Src was much more commonly
located to the cell membrane of prostate cells compared with the
ER-positive breast carcinomas. Figure 2 illustrates the staining
patterns observed in the ER-positive breast cancer specimens
compared with prostate cancer specimens.
Activated c-Src and patient outcome
High expression level (above the median value) of activated c-Src
within the nucleus of tumour cells was significantly associated with
improved overall survival (P¼0.047) and decreased recurrence in
tamoxifen-treated patients (P¼0.02), Figure 3A and B. On Cox
regression analysis this was not shown to be independent of
survival or recurrence. The location of activated c-Src around the
nucleus was also significant, tumours with uniform staining had
improved outcome in comparison with patients with only
perinuclear staining (Figure 3C, P¼0.0153). Activated c-Src within
the cell cytoplasm was not significantly associated with patient
outcome.
Activated c-Src and prognostic indices
Activated c-Src within the nucleus was associated with node
negativity and low NPI (Pearson’s w
2, P¼0.03 and P¼0.046,
respectively). Activated c-Src within the cytoplasm of cells was not
associated with nodal status, NPI, tumour grade or size. No
significant correlation was found with Ki67 (proliferative index).
In contrast when the cohort was subdivided by progesterone
receptor (PgR) status (histoscore 410), activated c-Src nuclear
expression remained highly significant in the ER and
PgRþsubgroup (n¼165, P¼0.004). However, in the ERþ/PgR-
negative subgroup significance was lost (n¼93, P¼0.56).
Progesterone receptor status was not available for four tumours
from our cohort of 262 patients. The cohort was not stratified for
HER2 status as only four tumours were found to be positive using
the Herceptest.
Total Src expression in ER-positive breast cancer
Of the 262 patients only 231 tumour samples were scored for total
Src expression. 95.8% (220 out of 231) of tumours expressed total
Src in the cytoplasm, median histoscore 97 (interquartile range
40–150). 70.6% (153 out of 230) of tumours expressed total Src in
the cell membrane, median histoscore 26 (interquartile range 0–
95). No total Src was seen within the cell nucleus. Total Src
expression (at any location) was not significantly associated with
any clinical parameters or patient outcome.
DISCUSSION
Although cell line studies strongly support the role of c-Src in
endocrine-resistant breast cancer progression, translational
studies investigating human breast tumour expression, activation
and correlation with clinical parameters are surprisingly limited.
Using a large cohort of ER-positive breast cancer patients treated
with adjuvant tamoxifen we have shown that high levels of
activated c-Src are present in over 50% of tumour specimens and
we also show that nuclear c-src activation is significantly
associated with improved overall and disease-free survival.
Subgroup analysis shows that this benefit is only seen in ERþ/
PgRþ patients and not within ERþ/PgR-negative group.
As c-Src is a non-receptor tyrosine kinase that is localised to the
intracellular membranes and cytoplasm of the cell, (Biscardi et al,
2000) it was surprising that in this study we rarely observed
activated c-Src in the cell membrane. However, antibody
specificity was confirmed by western blotting. A single 60kDa
band suggested that phosphorylated Src kinase was detected. In
addition, phosphorylation of c-Src (but not total c-Src) was
observed to decrease after treatment with increasing concentra-
tions of the Src kinase inhibitor dasatinib confirming that the
antibody detected only phosphorylated Src (Figure 1). Although
these experiments confirmed that the antibody used in the study
was specific for phosphorylated Src kinase, it did not answer the
question about the location of phosphorylated Src observed in this
cohort. We therefore stained prostate tumours to assess the
localisation of activated Src in a different tumour type. In prostate
cancer, the majority of staining observed for phosphorylated Src
Table 1 Patient clinical and pathological variables
Number Valid%
Grade
1 60 23.3
2 124 48.2
3 73 28.4
Unknown 5
Nodal status
0 128 53.3
1–3 72 30
4+ 40 16.7
Unknown 22
Histological type
Ductal 218 83.2
Lobular 20 7.6
Other (incl. unknown) 24 9.2
Size (mm)
T1(o20) 89 36.3
T2 (20–50) 149 59.1
T3 (450) 14 5.6
Unknown 10
NPI
o3.5 66 35.5
3.5–5.5 94 50.5
45.5 26 14
Unknown 76
Age (years)
o/¼50 42 16
450 220 84
Chemotherapy
Yes 68/262 26
No 194/262 74
Progesterone receptor (PgR) status
PgR+ 165 63
PgR  93 35
PgR unknown 4 1.5
NPI¼Nottingham Prognostic Index (grade+nodal status+0.02  size in mm).
Grade¼Bloom and Richardson grade. Nodal status¼number of positive nodes,
Histological type: ductal, invasive ductal carcinoma; lobular, invasive lobular
carcinoma; other includes mucinous, mucoid etc.
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swas located to the membrane and nuclear expression was rarely
observed. These results suggest that the lack of membrane staining
and high level of nuclear staining observed in this study was
associated with our ER-positive breast cancer cohort, and was not
a characteristic of the antibody used. However, the Y
416 sequence is
highly conserved among the src kinases so this does not exclude
detection of other src family kinases along with c-Src using this
antibody. Our detection of nuclear c-src expression and activation
is in line with recent literature as c-Src has been reported both
within the nucleus and nucleolus (David-Pfeuty et al, 1993; David-
Pfeuty and Nouvian-Dooghe, 1995) of other solid tumours. Earlier
immunohistochemical work showed that in non-malignant breast
cells c-Src is distributed within the cytoplasm, whereas in
malignant breast cells the majority of c-Src appears concentrated
around the nucleus (Verbeek et al, 1996).
In this study we found that high levels of activated c-Src was
present in over 50% tumour specimens analysed and nuclear
activated c-Src was significantly associated with improved overall
survival and decreased recurrence. Ito et al (2002) also found that
elevated activated c-Src was inversely correlated with biological
aggressiveness in 73 breast cancer specimens and suggested that c-
Src may have an important role in malignant transformation of
breast cells rather than malignant progression. Madan et al (2006)
subsequently showed that c-Src activation did not correlate with
the development of invasive tumour properties but correlated with
malignant transformation. In ductal carcinoma in situ, activated
c-Src was found to correlate with high tumour grade, high
proliferation and HER 2 positivity, suggesting that high c-Src
activity may identify a subset of DCIS at risk of disease progression
to invasive carcinoma (Wilson et al, 2006).
The body of evidence does, however, still support a role for c-Src
in malignant progression. Compared with adjacent normal tissues,
elevated Src expression and/or activity has been reported in a wide
range of tumour types, including breast cancer (Verbeek et al,
1996) and in many of these tissues, an increase in Src activity
correlates with disease stage or malignant potential (Aligayer et al,
2002; Weiner et al, 2003). Tumour cell lines possessing elevated Src
activity are often highly metastatic, displaying an increased
capacity for migration and invasion in vitro (Mao et al, 1997;
Jackson et al, 2000; Slack et al, 2001).
Recent in vitro breast cell line work, show overexpression and
over activity of Src during the acquisition of tamoxifen resistance
in ERþ cell line (Hiscox et al, 2005; Planas-Silva et al, 2006). Src
inhibition was seen to significantly reduce the invasive behaviour
of cells. Hiscox et al found that elevated Src kinase activity in
endocrine-resistance models was independent of Src gene or
protein level. Tamoxifen resistance may be either de novo (present
before tamoxifen treatment) or ‘acquired’. In this study all analysis
was performed on tumour samples taken before tamoxifen
treatment, and although we do not find that active c-Src correlates
with de novo endocrine resistance, it is interesting that within our
cohort the survival benefit was only in ERþ/PgRþ patients and
not in the ERþ/PgR negative group. PgR expression is a marker of
a functional ER and a number of laboratory studies have shown the
importance of molecular characteristics such as PgR and HER2 in
predicting tumour response to endocrine therapy. We have
reported earlier that ERþ/PgR-negative tumours are more likely
to relapse on tamoxifen (Tovey et al, 2005), and a number of other
laboratory studies report a reduction in PgR expression in ERþ
cells that is consistent with acquired tamoxifen resistance (Scott
et al, 2007). It is therefore possible that in tumours with a
functioning ER (ERþ/PgRþ) ‘active’ c-Src is in the nucleus and
not able to perform its role in promoting tumour progression.
Tumours acquiring tamoxifen resistance over time have an
adaptive change in growth factor signalling (such as a reduction
in PgR expression, increased EGFR expression), therefore Src
kinase being downstream of such signalling networks may not
become fully active until later during the development of
tamoxifen resistance. High levels of activated c-Src expression in
the cell cytoplasm have been reported in recurrent breast
carcinoma samples (Planas-Silva et al, 2006) although this
expression was not compared with the primary tumour sample.
Comparison of primary breast tumour c-Src expression with
expression in recurrent or metastatic tumours following endocrine
Prostate 
Breast
A
C D
B
Figure 2 The different localisation of activated c-Src, SrcpY
416 in prostate and breast tumour samples are shown. In breast tumours, activated c-Src was
most commonly present in the cell cytoplasm and the cell nucleus (A and B). In the prostate cancer (C and D), the majority of staining observed for
phosphorylated c-Src was located to the membrane, and nuclear expression was rarely observed.
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sresistance would be a preferable model. Within our laboratory we
have examined this in prostate cancer specimens. In hormone-
sensitive prostate cancer, active c-Src was associated with
improved survival but after development of hormone therapy
resistance, active c-Src was associated with reduced time to death
(unpublished data).
It is also likely that our patient cohort represents a good
prognostic group and that the aggressive phenotype associated
with Src kinase is limited to poor prognostic cancers. Indeed, Finn
et al (2007) recently reported a highly significant relationship
between breast cancer cell line subtype based on gene expression
of cytokeratins and sensitivity to src kinase inhibition, suggesting
that the ‘triple negative’ breast cancers were most likely to benefit
from Src inhibition. ER-negative tumours correlate with poor
tumour differentiation, high proliferation rate and other unfavour-
able characteristics, and are, in general, considered a more
aggressive breast carcinoma. An inverse correlation between Src
and ER levels has been reported, ER-negative primary breast
cancer and cell lines showed increased Src levels and/or activity
compared with ERþcancers (Chu et al, 2007).
In conclusion, we found that elevated levels of activated c-Src
within the cell nucleus of ERþ breast cancer were associated with
improved patient outcome in a large cohort of Tamoxifen-treated
ER-positive patients. Although we are unable to substantiate the
in vitro studies suggesting a role for c-Src in tamoxifen resistance
we feel that further clarification defining the role of c-Src in the
different subtypes of breast cancer, particularly in ER-negative
breast cancer and recurrent tumours, is warranted as this likely
represents the group in which targeted Src Kinase inhibition may
be beneficial to patient outcome.
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